GILENYA is indicated as single disease modifying therapy in highly active relapsing-remitting multiple sclerosis for the following adult patient groups and paediatric patients aged 10 years and older*³:

*The safety and efficacy of GILENYA in children aged below 10 years have not been established. No data are available.
There are very limited data available in children between 10 and 12 years old.

Patient profiles are fictional. For illustrative purposes only.

ARR, annualised relapse rate; EDSS, expanded disability status scale; Gd+, gadolinium-enhancing; MRI, magnetic resonance imaging.

References

1. Ziemssen T et al. Poster P6.393 presented at the 70th AAN Meeting, 21–27 April 2018, Los Angeles, CA, USA.
2. Ziemssen T et al. Poster P5.365 presented at the 70th AAN Meeting, 21–27 April 2018, Los Angeles, CA, USA.
3. GILENYA (fingolimod) Summary of Product Characteristics.